A decision posted to the site of the U.S. District Court for the District of Delaware indicates that the court concludes that Acadia Pharmaceuticals (ACAD) “demonstrated by a preponderance of the evidence that Aurubindo infringes claims 4 and 5 of U.S. Patent No. 11,452,721.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders
- ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth
- Positive Outlook for ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Strategic Growth Initiatives and Promising Pipeline Developments
- Positive Growth Outlook for ACADIA Pharmaceuticals Driven by Daybue’s Expanding Patient Base and Market Potential
- ACADIA Pharmaceuticals: Promising Growth with Strong Sales Projections and Strategic Advancements